$CBIO 8-K SEC Filings

Filed On	Filing
15 Oct 2026	8-K: Other Events On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plu...
30 Jul 2026	8-K: Results of Operations and Financial Condition
15 Jul 2026	8-K: Other Events
14 Jul 2026	8-K: Results of Operations and Financial Condition
03 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
29 Apr 2026	8-K: Results of Operations and Financial Condition
26 Feb 2026	8-K: Results of Operations and Financial Condition
04 Dec 2025	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
06 Nov 2025	8-K: Results of Operations and Financial Condition
31 Jul 2025	8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
18 Jun 2025	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +9 more
06 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure +1 more
30 May 2025	8-K: Other Events
29 Apr 2025	8-K: Entry into a Material Definitive Agreement
25 Feb 2025	8-K: Termination of a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
14 Feb 2025	8-K: Entry into a Material Definitive Agreement
31 Jan 2025	8-K: Departure/Election of Directors or Officers; Compensation
13 Jan 2025	8-K: Regulation FD Disclosure
26 Dec 2024	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
07 Nov 2024	8-K: Regulation FD Disclosure

Comments